Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical proxymetacaine versus subconjunctival lignocaine for anesthesia during intravitreal Lucentis injection
2010-022644-21Phase 4Completed
- Sponsor
- University Hospitals Plymouth
- Start
- Oct 2010
- Modality
- Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of proparacaine, lidocaine and ranibizumab in exudative macular degeneration (2 arms), sponsored by University Hospitals Plymouth. Primary endpoints: Numeric pain analogue scale at 0.25 hour after injection and Telephone verbal numeric pain scale for overall procedural comfort. Started Oct 2010; status: completed.
02
Drugs
proparacainelidocaineranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2010-022644-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022644-21.